Cardiol Historical Balance Sheet

CRDL Stock

USD 1.33 0.03 2.21%

Trend analysis of Cardiol Therapeutics Class balance sheet accounts such as Short Long Term Debt Total of 133.9 K, Other Current Liabilities of 622.2 K or Total Current Liabilities of 5.5 M provides information on Cardiol Therapeutics' total assets, liabilities, and equity, which is the actual value of Cardiol Therapeutics to its prevalent stockholders. By breaking down trends over time using Cardiol Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Cardiol Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cardiol Therapeutics is a good buy for the upcoming year.

Cardiol Therapeutics Inventory

(239,291)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

About Cardiol Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Cardiol Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Cardiol Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Cardiol Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Cardiol currently owns. An asset can also be divided into two categories, current and non-current.

Cardiol Therapeutics Balance Sheet Chart

At this time, Cardiol Therapeutics' Total Current Assets are quite stable compared to the past year. Intangible Assets is expected to rise to about 371 K this year, although the value of Other Current Liabilities will most likely fall to about 622.2 K.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Retained Earnings Intangible Assets

Total Assets

Total assets refers to the total amount of Cardiol Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cardiol Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Cardiol Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cardiol Therapeutics Class are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Intangible Assets

Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.

Most accounts from Cardiol Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Cardiol Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	117.6K	72.9K	174.3K	133.9K
Total Assets	87.9M	62.0M	36.7M	38.6M

Short Long Term Debt Total Total Assets

Cardiol Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Intangible Assets	Common Stock	Property Plant Equipment	Inventory
Total Assets		-0.67	0.84	0.96	1.0	0.96	0.55	-1.0	-0.76	0.79	1.0	-0.29	0.71	1.0	0.49	0.73	-0.72	0.82	0.96	0.96	1.0	0.96	-0.8	0.91	0.55	-0.74
Short Long Term Debt Total	-0.67		-0.52	-0.71	-0.66	-0.59	-0.49	0.71	0.65	-0.63	-0.71	0.18	-0.31	-0.71	-0.19	-0.75	0.96	-0.65	-0.71	-0.59	-0.67	-0.59	0.65	-0.68	-0.49	0.7
Other Current Liab	0.84	-0.52		0.74	0.85	0.76	0.42	-0.84	-0.4	0.39	0.85	-0.02	0.41	0.85	0.29	0.4	-0.57	0.5	0.74	0.76	0.84	0.76	-0.48	0.63	0.42	-0.49
Total Current Liabilities	0.96	-0.71	0.74		0.95	0.98	0.54	-0.97	-0.86	0.9	0.97	-0.41	0.74	0.97	0.39	0.87	-0.74	0.92	1.0	0.98	0.97	0.98	-0.9	0.98	0.55	-0.79
Total Stockholder Equity	1.0	-0.66	0.85	0.95		0.94	0.55	-0.99	-0.74	0.76	0.99	-0.26	0.7	0.99	0.51	0.7	-0.72	0.79	0.95	0.94	1.0	0.94	-0.78	0.89	0.55	-0.73
Net Tangible Assets	0.96	-0.59	0.76	0.98	0.94		0.57	-0.95	-0.84	0.87	0.95	-0.36	0.8	0.95	0.46	0.83	-0.65	0.91	0.98	1.0	0.96	1.0	-0.89	0.97	0.57	-0.78
Property Plant And Equipment Net	0.55	-0.49	0.42	0.54	0.55	0.57		-0.52	-0.66	0.5	0.51	0.42	0.8	0.51	0.76	0.54	-0.69	0.71	0.54	0.57	0.55	0.56	-0.75	0.65	1.0	-0.91
Net Debt	-1.0	0.71	-0.84	-0.97	-0.99	-0.95	-0.52		0.77	-0.8	-1.0	0.34	-0.67	-1.0	-0.42	-0.75	0.75	-0.82	-0.97	-0.95	-1.0	-0.95	0.8	-0.91	-0.51	0.73
Retained Earnings	-0.76	0.65	-0.4	-0.86	-0.74	-0.84	-0.66	0.77		-0.91	-0.76	0.39	-0.8	-0.76	-0.46	-0.91	0.69	-0.95	-0.86	-0.84	-0.76	-0.84	0.97	-0.93	-0.66	0.9
Accounts Payable	0.79	-0.63	0.39	0.9	0.76	0.87	0.5	-0.8	-0.91		0.8	-0.52	0.78	0.8	0.38	0.95	-0.65	0.95	0.9	0.87	0.79	0.87	-0.93	0.95	0.5	-0.77
Cash	1.0	-0.71	0.85	0.97	0.99	0.95	0.51	-1.0	-0.76	0.8		-0.33	0.67	1.0	0.42	0.75	-0.74	0.82	0.97	0.95	1.0	0.95	-0.8	0.91	0.51	-0.73
Non Current Assets Total	-0.29	0.18	-0.02	-0.41	-0.26	-0.36	0.42	0.34	0.39	-0.52	-0.33		-0.03	-0.33	0.38	-0.45	-0.01	-0.31	-0.42	-0.36	-0.29	-0.37	0.27	-0.35	0.43	-0.03
Long Term Debt	0.71	-0.31	0.41	0.74	0.7	0.8	0.8	-0.67	-0.8	0.78	0.67	-0.03		0.67	0.7	0.69	-0.49	0.88	0.74	0.79	0.71	0.79	-0.89	0.84	0.8	-0.85
Cash And Short Term Investments	1.0	-0.71	0.85	0.97	0.99	0.95	0.51	-1.0	-0.76	0.8	1.0	-0.33	0.67		0.42	0.75	-0.74	0.82	0.97	0.95	1.0	0.95	-0.8	0.91	0.51	-0.73
Net Receivables	0.49	-0.19	0.29	0.39	0.51	0.46	0.76	-0.42	-0.46	0.38	0.42	0.38	0.7	0.42		0.31	-0.39	0.46	0.39	0.46	0.49	0.46	-0.52	0.49	0.76	-0.63
Common Stock Shares Outstanding	0.73	-0.75	0.4	0.87	0.7	0.83	0.54	-0.75	-0.91	0.95	0.75	-0.45	0.69	0.75	0.31		-0.74	0.94	0.87	0.83	0.73	0.83	-0.92	0.92	0.54	-0.8
Non Current Liabilities Total	-0.72	0.96	-0.57	-0.74	-0.72	-0.65	-0.69	0.75	0.69	-0.65	-0.74	-0.01	-0.49	-0.74	-0.39	-0.74		-0.72	-0.73	-0.64	-0.72	-0.64	0.73	-0.74	-0.69	0.82
Other Stockholder Equity	0.82	-0.65	0.5	0.92	0.79	0.91	0.71	-0.82	-0.95	0.95	0.82	-0.31	0.88	0.82	0.46	0.94	-0.72		0.92	0.91	0.82	0.91	-0.99	0.98	0.71	-0.91
Total Liab	0.96	-0.71	0.74	1.0	0.95	0.98	0.54	-0.97	-0.86	0.9	0.97	-0.42	0.74	0.97	0.39	0.87	-0.73	0.92		0.98	0.97	0.98	-0.89	0.98	0.54	-0.79
Net Invested Capital	0.96	-0.59	0.76	0.98	0.94	1.0	0.57	-0.95	-0.84	0.87	0.95	-0.36	0.79	0.95	0.46	0.83	-0.64	0.91	0.98		0.96	1.0	-0.89	0.97	0.57	-0.77
Total Current Assets	1.0	-0.67	0.84	0.97	1.0	0.96	0.55	-1.0	-0.76	0.79	1.0	-0.29	0.71	1.0	0.49	0.73	-0.72	0.82	0.97	0.96		0.96	-0.8	0.91	0.55	-0.74
Net Working Capital	0.96	-0.59	0.76	0.98	0.94	1.0	0.56	-0.95	-0.84	0.87	0.95	-0.37	0.79	0.95	0.46	0.83	-0.64	0.91	0.98	1.0	0.96		-0.89	0.97	0.56	-0.77
Intangible Assets	-0.8	0.65	-0.48	-0.9	-0.78	-0.89	-0.75	0.8	0.97	-0.93	-0.8	0.27	-0.89	-0.8	-0.52	-0.92	0.73	-0.99	-0.89	-0.89	-0.8	-0.89		-0.97	-0.75	0.94
Common Stock	0.91	-0.68	0.63	0.98	0.89	0.97	0.65	-0.91	-0.93	0.95	0.91	-0.35	0.84	0.91	0.49	0.92	-0.74	0.98	0.98	0.97	0.91	0.97	-0.97		0.65	-0.87
Property Plant Equipment	0.55	-0.49	0.42	0.55	0.55	0.57	1.0	-0.51	-0.66	0.5	0.51	0.43	0.8	0.51	0.76	0.54	-0.69	0.71	0.54	0.57	0.55	0.56	-0.75	0.65		-0.91
Inventory	-0.74	0.7	-0.49	-0.79	-0.73	-0.78	-0.91	0.73	0.9	-0.77	-0.73	-0.03	-0.85	-0.73	-0.63	-0.8	0.82	-0.91	-0.79	-0.77	-0.74	-0.77	0.94	-0.87	-0.91

Click cells to compare fundamentals

Cardiol Therapeutics Account Relationship Matchups

Cardiol Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	15.5M	15.9M	87.9M	62.0M	36.7M	38.6M
Short Long Term Debt Total	190.8K	156.6K	117.6K	72.9K	174.3K	133.9K
Other Current Liab	640.1K	696.1K	7.4M	1.4M	655.0K	622.2K
Total Current Liabilities	690.5K	2.5M	11.6M	9.8M	8.3M	5.5M
Total Stockholder Equity	14.7M	13.3M	76.2M	52.2M	28.2M	33.0M
Net Tangible Assets	14.1M	12.8M	75.9M	51.9M	59.7M	32.7M
Property Plant And Equipment Net	584.0K	479.6K	356.5K	295.7K	337.1K	329.6K
Net Debt	(6.8M)	(13.9M)	(83.8M)	(59.4M)	(34.8M)	(36.5M)
Retained Earnings	(31.2M)	(51.9M)	(83.5M)	(114.4M)	(142.6M)	(135.4M)
Accounts Payable	561.3K	1.8M	4.1M	8.3M	7.6M	3.9M
Cash	7.0M	14.0M	83.9M	59.5M	34.9M	34.3M
Non Current Assets Total	1.1M	943.2K	735.7K	590.5K	547.4K	610.6K
Cash And Short Term Investments	7.0M	14.0M	83.9M	59.5M	34.9M	34.3M
Net Receivables	927.9K	219.9K	407.1K	480.2K	279.9K	452.2K
Common Stock Shares Outstanding	25.8M	29.9M	43.2M	62.5M	64.5M	41.5M
Liabilities And Stockholders Equity	15.5M	15.9M	87.9M	62.0M	36.7M	38.6M
Non Current Liabilities Total	140.3K	104.7K	72.9K	22.4K	158.5K	109.5K
Other Stockholder Equity	4.8M	8.8M	12.7M	15.6M	18.8M	10.0M
Total Liab	830.8K	2.6M	11.6M	9.8M	8.5M	5.7M
Net Invested Capital	14.7M	13.3M	76.2M	52.2M	60.0M	33.4M
Total Current Assets	14.4M	14.9M	87.1M	61.4M	36.2M	37.8M
Net Working Capital	13.7M	12.4M	75.6M	51.6M	59.4M	32.5M
Intangible Assets	548.1K	463.7K	379.2K	294.8K	210.4K	371.0K
Common Stock	39.4M	51.9M	142.9M	147.5M	148.5M	89.8M
Property Plant Equipment	584.0K	479.6K	356.5K	295.7K	340.1K	322.7K
Inventory	1.1M	18.0K	339.1K	(279.9K)	(251.9K)	(239.3K)
Other Current Assets	5.4M	347.8K	2.8M	1.5M	1.2M	1.6M
Capital Stock	39.4M	51.9M	142.9M	147.5M	169.7M	92.1M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Cardiol Therapeutics is a strong investment it is important to analyze Cardiol Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiol Therapeutics' future performance. For an informed investment choice regarding Cardiol Stock, refer to the following important reports:

How To Invest In Cardiol

Details

Is Cardiol Stock a good investment?

Details

What is Cardiol Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.38)

Return On Assets

(0.54)

Return On Equity

(1.08)

The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cardiol Historical Balance Sheet

Cardiol Therapeutics Inventory

(239,291)

About Cardiol Balance Sheet Analysis

Cardiol Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Retained Earnings

Intangible Assets

Cardiol Therapeutics balance sheet Correlations

Cardiol Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cardiol Therapeutics balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Total Stockholder Equity

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Assets
Intangible Assets	- 0.99	Other Stockholder Equity
Net Debt	- 0.99	Total Stockholder Equity